ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
March 2026
Nuclear Technology
February 2026
Fusion Science and Technology
April 2026
Latest News
NRC approves TerraPower construction permit
Today, the Nuclear Regulatory Commission announced that it has approved TerraPower’s construction permit application for Kemmerer Unit 1, the company’s first deployment of Natrium, its flagship sodium fast reactor.
This approval is a significant milestone on three fronts. For TerraPower, it represents another step forward in demonstrating its technology. For the Department of Energy, it reflects progress (despite delays) for the Advanced Reactor Demonstration Program (ARDP). For the NRC, it is the first approval granted to a commercial reactor in nearly a decade—and the first approval of a commercial non–light water reactor in more than 40 years.
Hungyuan B. Liu, Francis J. Patti
Nuclear Technology | Volume 116 | Number 3 | December 1996 | Pages 373-377
Technical Note | Heat Transfer and Fluid Flow | doi.org/10.13182/NT96-A35292
Articles are hosted by Taylor and Francis Online.
Recent changes are updated for the proposed modification to use a fission plate converter and a matching filter/moderator assembly in a newly designed beam shutter to enhance the epithermal neutron beam for patient irradiations during boron neutron capture therapy (BNCT) at the Brookhaven Medical Research Reactor, Brookhaven National Laboratory. Engineering design of the new beam shutter system has been completed, and design review is under way. With this upgrade, the epithermal neutron flux could be increased up to seven times higher than the present beam, and the fast-neutron dose per epithermal neutron fluence could be reduced to near half. Such an enhanced epithermal neutron beam would increase the effectiveness of clinical BNCT by allowing increased doses to the tumor with similar or lesser doses to normal tissues.